TSE:SVA Sernova Q1 2024 Earnings Report C$0.21 -0.01 (-4.55%) As of 10:16 AM Eastern Earnings HistoryForecast Sernova EPS ResultsActual EPS-C$0.03Consensus EPS -C$0.03Beat/MissMet ExpectationsOne Year Ago EPSN/ASernova Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ASernova Announcement DetailsQuarterQ1 2024Date3/18/2024TimeN/AConference Call DateWednesday, March 13, 2024Conference Call Time7:00PM ETConference Call ResourcesReportEarnings HistoryCompany ProfilePowered by Earnings DocumentsReport Sernova Earnings HeadlinesSernova Biotherapeutics Inc's (TSE:SVA) Shift From Loss To ProfitMarch 23, 2025 | finance.yahoo.comSernova Biotherapeutics Inc (SVA.TO)March 19, 2025 | finance.yahoo.comThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.April 24, 2025 | Paradigm Press (Ad)Sernova Corp.: Sernova Announces Appointment of Ross Haghighat as Chair of the Board and a Change of Name to Sernova BiotherapeuticsFebruary 11, 2025 | finanznachrichten.deJobs Reports Due for Next WeekJanuary 31, 2025 | theglobeandmail.comSernova Announces Appointment of Ross Haghighat as Chair of the Board and a Change of Name to Sernova BiotherapeuticsJanuary 30, 2025 | markets.businessinsider.comSee More Sernova Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Sernova? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sernova and other key companies, straight to your email. Email Address About SernovaSernova (TSE:SVA) Biotherapeutics is a clinical-stage company developing regenerative medicine therapeutics combining its Cell Pouch with human donor cells or stem cells to create a bio-hybrid organ. A bio-hybrid organ refers to a medical device designed to be implanted into the human body, where it integrates with existing living tissue to replicate or enhance the function of a natural organ, essentially aiming to restore normal organ function by combining living cells with non-living materials to mimic the properties of the original organ and seamlessly interact with surrounding tissues. This innovative approach aims to deliver a potentially revolutionary treatment for patients with chronic diseases, initially focusing on Type 1 diabetes and thyroid disorders.View Sernova ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Amazon's Earnings Could Fuel a Rapid Breakout Tesla Earnings Miss, But Musk Refocuses and Bulls ReactQualcomm’s Range Narrows Ahead of Earnings as Bulls Step InWhy It May Be Time to Buy CrowdStrike Stock Heading Into EarningsCan IBM’s Q1 Earnings Spark a Breakout for the Stock?Genuine Parts: Solid Earnings But Economic Uncertainties RemainBreaking Down Taiwan Semiconductor's Earnings and Future Upside Upcoming Earnings AbbVie (4/25/2025)AON (4/25/2025)Colgate-Palmolive (4/25/2025)HCA Healthcare (4/25/2025)NatWest Group (4/25/2025)Cadence Design Systems (4/28/2025)Welltower (4/28/2025)Waste Management (4/28/2025)AstraZeneca (4/29/2025)Booking (4/29/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
